{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T05:34:49Z","timestamp":1768887289394,"version":"3.49.0"},"reference-count":303,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.det.2019.05.015","type":"journal-article","created":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T18:05:55Z","timestamp":1566842755000},"page":"583-606","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Phakomatoses"],"prefix":"10.1016","volume":"37","author":[{"given":"Benjamin","family":"Becker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Roy E.","family":"Strowd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.det.2019.05.015_bib1","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/ejhg.2014.210","article-title":"Somatic neurofibromatosis type 1 (NF1) inactivation events in cutaneous neurofibromas of a single NF1 patient","volume":"23","author":"Emmerich","year":"2015","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.det.2019.05.015_bib2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/B978-0-444-53485-9.00027-1","article-title":"Neurocutaneous syndromes","volume":"135","author":"Islam","year":"2016","journal-title":"Handb Clin Neurol"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<1::AID-AJMG3>3.0.CO;2-8","article-title":"Epidemiology of neurofibromatosis type 1","volume":"89","author":"Friedman","year":"1999","journal-title":"Am J Med Genet"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archderm.141.1.71","article-title":"Prevalence of neurofibromatosis 1 in German children at elementary school enrollment","volume":"141","author":"Lammert","year":"2005","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib5","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ajmg.a.33139","article-title":"Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service","volume":"152A","author":"Evans","year":"2010","journal-title":"Am J Med Genet A"},{"issue":"9678","key":"10.1016\/j.det.2019.05.015_bib6","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic fibrosis","volume":"373","author":"O'Sullivan","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.det.2019.05.015_bib7","series-title":"GeneReviews\u00ae [Internet]","article-title":"Neurofibromatosis 1. 1998 Oct 2","author":"Friedman","year":"1993"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1590\/abd1806-4841.20132125","article-title":"Neurofibromatosis: chronological history and current issues","volume":"88","author":"Antonio","year":"2013","journal-title":"An Bras Dermatol"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-4362.1980.tb01998.x","article-title":"Antique illustrations of neurofibromatosis","volume":"19","author":"Zanca","year":"1980","journal-title":"Int J Dermatol"},{"issue":"6286","key":"10.1016\/j.det.2019.05.015_bib10","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/346696a0","article-title":"Oncoproteins. GAPs in understanding ras","volume":"346","author":"Wigler","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.det.2019.05.015_bib11","series-title":"A\u00a0clinical, pathological, and genetic study of multiple neurofibromatosis","author":"Crowe","year":"1956"},{"key":"10.1016\/j.det.2019.05.015_bib12","first-page":"67","article-title":"Neurofibromatosis. A clinical and genetic study of 96 cases in Gothenburg, Sweden","volume":"95","author":"Samuelsson","year":"1981","journal-title":"Acta Derm Venereol Suppl (Stockh)"},{"issue":"11","key":"10.1016\/j.det.2019.05.015_bib13","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/jmg.26.11.704","article-title":"A\u00a0genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity","volume":"26","author":"Huson","year":"1989","journal-title":"J\u00a0Med Genet"},{"issue":"4","key":"10.1016\/j.det.2019.05.015_bib14","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/jmedgenet-2011-100562","article-title":"Life expectancy in hereditary cancer predisposing diseases: an observational study","volume":"49","author":"Wilding","year":"2012","journal-title":"J\u00a0Med Genet"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib15","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/ng1194-218","article-title":"Screening for truncated NF1 proteins","volume":"8","author":"Heim","year":"1994","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.det.2019.05.015_bib16","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/(SICI)1098-1004(1997)9:6<548::AID-HUMU8>3.0.CO;2-Y","article-title":"NF1 mutation analysis using a combined heteroduplex\/SSCP approach","volume":"9","author":"Abernathy","year":"1997","journal-title":"Hum Mutat"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/humu.10299","article-title":"Screening 500 unselected neurofibromatosis 1 patients for deletions of the NF1 gene","volume":"23","author":"Kluwe","year":"2004","journal-title":"Hum Mutat"},{"issue":"9","key":"10.1016\/j.det.2019.05.015_bib18","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1136\/jmg.2009.075937","article-title":"Clinical characterisation of 29 neurofibromatosis type-1 patients with molecularly ascertained 1.4 Mb type-1 NF1 deletions","volume":"47","author":"Mautner","year":"2010","journal-title":"J\u00a0Med Genet"},{"issue":"6","key":"10.1016\/j.det.2019.05.015_bib19","doi-asserted-by":"crossref","first-page":"E1506","DOI":"10.1002\/humu.21271","article-title":"NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype","volume":"31","author":"Pasmant","year":"2010","journal-title":"Hum Mutat"},{"key":"10.1016\/j.det.2019.05.015_bib20","series-title":"Neurofibromatosis type 1","first-page":"187","article-title":"NF1 microdeletions and their underlying mutational mechanisms","author":"Kehrer-Sawatzki","year":"2012"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib21","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/ng0995-90","article-title":"Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene","volume":"11","author":"Colman","year":"1995","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib22","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1086\/519562","article-title":"Molecular dissection of isolated disease features in mosaic neurofibromatosis type 1","volume":"81","author":"Maertens","year":"2007","journal-title":"Am J Hum Genet"},{"issue":"4","key":"10.1016\/j.det.2019.05.015_bib23","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/sj.jid.5701095","article-title":"Somatic mutation analysis in NF1 cafe au lait spots reveals two NF1 hits in the melanocytes","volume":"128","author":"De Schepper","year":"2008","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2019.05.015_bib24","series-title":"Neurofibromatosis type 1","first-page":"211","article-title":"The somatic mutational spectrum of the NF1 gene","author":"Upadhyaya","year":"2012"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib25","doi-asserted-by":"crossref","first-page":"e0119030","DOI":"10.1371\/journal.pone.0119030","article-title":"Double NF1 inactivation affects adrenocortical function in NF1Prx1 mice and a human patient","volume":"10","author":"Kobus","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib26","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.cell.2008.08.041","article-title":"Nf1-dependent tumors require a microenvironment containing Nf1+\/-- and c-kit-dependent bone marrow","volume":"135","author":"Yang","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.det.2019.05.015_bib27","series-title":"Neurofibromatoses in clinical practice","author":"Ferner","year":"2011"},{"key":"10.1016\/j.det.2019.05.015_bib28","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/B978-0-444-52902-2.00053-9","article-title":"Neurofibromatosis type 1 (NF1): diagnosis and management","volume":"115","author":"Ferner","year":"2013","journal-title":"Handb Clin Neurol"},{"issue":"8","key":"10.1016\/j.det.2019.05.015_bib29","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1001\/archdermatol.2009.169","article-title":"Predictive value of cafe au lait macules at initial consultation in the diagnosis of neurofibromatosis type 1","volume":"145","author":"Nunley","year":"2009","journal-title":"Arch Dermatol"},{"issue":"11","key":"10.1016\/j.det.2019.05.015_bib30","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/humu.22152","article-title":"Review and update of SPRED1 mutations causing Legius syndrome","volume":"33","author":"Brems","year":"2012","journal-title":"Hum Mutat"},{"key":"10.1016\/j.det.2019.05.015_bib31","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ebiom.2016.04.005","article-title":"Comprehensive RNA analysis of the NF1 gene in classically affected NF1 affected individuals meeting NIH criteria has high sensitivity and mutation negative testing is reassuring in isolated cases with pigmentary features only","volume":"7","author":"Evans","year":"2016","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.det.2019.05.015_bib32","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/cge.12904","article-title":"Connections between constitutional mismatch repair deficiency syndrome and neurofibromatosis type 1","volume":"91","author":"Wimmer","year":"2017","journal-title":"Clin Genet"},{"issue":"5","key":"10.1016\/j.det.2019.05.015_bib33","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/ajmg.a.35297","article-title":"Cafe-au-lait macules and intertriginous freckling in piebaldism: clinical overlap with neurofibromatosis type 1 and Legius syndrome","volume":"158a","author":"Stevens","year":"2012","journal-title":"Am J Med Genet A"},{"issue":"10","key":"10.1016\/j.det.2019.05.015_bib34","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1634\/theoncologist.2012-0162","article-title":"Clinical features of schwannomatosis: a retrospective analysis of 87 patients","volume":"17","author":"Merker","year":"2012","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib35","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1399-0004.1996.tb04328.x","article-title":"Neurofibromatosis\/Noonan phenotype: a variable feature of type 1 neurofibromatosis","volume":"49","author":"Colley","year":"1996","journal-title":"Clin Genet"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib36","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/gcc.20289","article-title":"Spectrum of single- and multiexon NF1 copy number changes in a cohort of 1,100 unselected NF1 patients","volume":"45","author":"Wimmer","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.det.2019.05.015_bib37","first-page":"63","article-title":"NF1 mutational spectrum","volume":"vol. 16","author":"Messiaen","year":"2008"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib38","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jmoldx.2010.09.002","article-title":"A\u00a0highly sensitive genetic protocol to detect NF1 mutations","volume":"13","author":"Valero","year":"2011","journal-title":"J\u00a0Mol Diagn"},{"issue":"11","key":"10.1016\/j.det.2019.05.015_bib39","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/humu.22392","article-title":"NF1 molecular characterization and neurofibromatosis type I genotype-phenotype correlation: the French experience","volume":"34","author":"Sabbagh","year":"2013","journal-title":"Hum Mutat"},{"issue":"4","key":"10.1016\/j.det.2019.05.015_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/genes9040216","article-title":"Accurate classification of NF1 gene variants in 84 Italian patients with neurofibromatosis type 1","volume":"9","author":"Stella","year":"2018","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.det.2019.05.015_bib41","series-title":"Dermatology","first-page":"985","article-title":"Neurofibromatosis and tuberous sclerosis complex","author":"Tsao","year":"2018"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib42","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1053\/j.seminoncol.2016.02.029","article-title":"Cutaneous manifestations in neuro-oncology: clinically relevant tumor and treatment associated dermatologic findings","volume":"43","author":"Strowd","year":"2016","journal-title":"Semin Oncol"},{"issue":"217","key":"10.1016\/j.det.2019.05.015_bib43","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/adc.41.217.316","article-title":"Diagnostic value of the cafe-au-lait spot in children","volume":"41","author":"Whitehouse","year":"1966","journal-title":"Arch Dis Child"},{"issue":"8","key":"10.1016\/j.det.2019.05.015_bib44","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/adc.57.8.631","article-title":"Cafe-au-lait spots in schoolchildren","volume":"57","author":"Burwell","year":"1982","journal-title":"Arch Dis Child"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib45","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/jmg.2006.045906","article-title":"Guidelines for the diagnosis and management of individuals with neurofibromatosis 1","volume":"44","author":"Ferner","year":"2007","journal-title":"J\u00a0Med Genet"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib46","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000327379","article-title":"Evolving pattern with age of cutaneous signs in neurofibromatosis type 1: a cross-sectional study of 728 patients","volume":"222","author":"Duong","year":"2011","journal-title":"Dermatology"},{"key":"10.1016\/j.det.2019.05.015_bib47","series-title":"Fitzpatrick\u2019s dermatology in general medicine","first-page":"1825","article-title":"The neurofibromatoses","author":"Pivnick","year":"2003"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib48","first-page":"197","article-title":"A\u00a0clinical study of type 1 neurofibromatosis in north west England","volume":"36","author":"McGaughran","year":"1999","journal-title":"J\u00a0Med Genet"},{"issue":"6","key":"10.1016\/j.det.2019.05.015_bib49","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1542\/peds.90.6.924","article-title":"Diagnostic outcome in children with multiple cafe au lait spots","volume":"90","author":"Korf","year":"1992","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib50","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<23::AID-AJMG6>3.0.CO;2-#","article-title":"Pathology of tumors of the peripheral nerve sheath in type 1 neurofibromatosis","volume":"89","author":"Woodruff","year":"1999","journal-title":"Am J Med Genet"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib51","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ajpath.2010.10.041","article-title":"The development of cutaneous neurofibromas","volume":"178","author":"Jouhilahti","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.det.2019.05.015_bib52","series-title":"Neurofibromatosis: phenotype, natural history, and pathogenesis","first-page":"28","article-title":"An overview of NF-1: dysplasia and neoplasia","author":"Riccardi","year":"1992"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib53","doi-asserted-by":"crossref","first-page":"398","DOI":"10.2340\/00015555-2241","article-title":"Clinical characteristics of pruritus in neurofibromatosis 1","volume":"96","author":"Brenaut","year":"2016","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib54","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<31::AID-AJMG7>3.0.CO;2-W","article-title":"Plexiform neurofibromas","volume":"89","author":"Korf","year":"1999","journal-title":"Am J Med Genet"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib55","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjd.13966","article-title":"Neurofibromatosis type 1: neurofibromas and sex","volume":"174","author":"Sbidian","year":"2016","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib56","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/s-0038-1627471","article-title":"Neurofibromatosis and schwannomatosis","volume":"38","author":"Plotkin","year":"2018","journal-title":"Semin Neurol"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib57","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/(SICI)1096-8628(19961202)66:1<7::AID-AJMG2>3.0.CO;2-R","article-title":"Neurofibromatosis type 1 and pregnancy","volume":"66","author":"Dugoff","year":"1996","journal-title":"Am J Med Genet"},{"issue":"12","key":"10.1016\/j.det.2019.05.015_bib58","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/ajmg.a.32301","article-title":"The role of steroid hormones in the NF1 phenotype: focus on pregnancy","volume":"146A","author":"Roth","year":"2008","journal-title":"Am J Med Genet A"},{"issue":"12","key":"10.1016\/j.det.2019.05.015_bib59","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/gcc.20921","article-title":"Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors","volume":"50","author":"Beert","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib60","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.0736-8046.2004.21201.x","article-title":"Juvenile xanthogranuloma associated with neurofibromatosis 1: 14 patients without evidence of hematologic malignancies","volume":"21","author":"Cambiaghi","year":"2004","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib61","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamadermatol.2013.6434","article-title":"Juvenile xanthogranuloma and nevus anemicus in the diagnosis of neurofibromatosis type 1","volume":"150","author":"Ferrari","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib62","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jaad.2014.02.049","article-title":"Juvenile xanthogranulomas are highly prevalent but transient in young children with neurofibromatosis type 1","volume":"71","author":"Fenot","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2019.05.015_bib63","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jaad.2013.06.039","article-title":"Nevus anemicus in neurofibromatosis type 1: a potential new diagnostic criterion","volume":"69","author":"Marque","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib64","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/pde.12525","article-title":"Nevus anemicus: a distinctive cutaneous finding in neurofibromatosis type 1","volume":"32","author":"Hernandez-Martin","year":"2015","journal-title":"Pediatr Dermatol"},{"issue":"18","key":"10.1016\/j.det.2019.05.015_bib65","doi-asserted-by":"crossref","first-page":"7393","DOI":"10.1158\/0008-5472.CAN-09-1752","article-title":"Glomus tumors in neurofibromatosis type 1: genetic, functional, and clinical evidence of a novel association","volume":"69","author":"Brems","year":"2009","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.det.2019.05.015_bib66","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ejhg.2011.113","article-title":"Mortality in neurofibromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989","volume":"19","author":"Evans","year":"2011","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib67","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/sj.bjc.6603227","article-title":"A\u00a0prospective study of neurofibromatosis type 1 cancer incidence in the UK","volume":"95","author":"Walker","year":"2006","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.det.2019.05.015_bib68","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/pbc.22462","article-title":"Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1","volume":"54","author":"Huttner","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"10.1016\/j.det.2019.05.015_bib69","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/pbc.25556","article-title":"Rhabdomyosarcomas in children with neurofibromatosis type I: a national historical cohort","volume":"62","author":"Crucis","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"16","key":"10.1016\/j.det.2019.05.015_bib70","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.2169\/internalmedicine.53.2012","article-title":"Coexistence of gastrointestinal stromal tumors (GISTs) and pheochromocytoma in three cases\u00a0of neurofibromatosis type 1 (NF1) with a review of the literature","volume":"53","author":"Gorgel","year":"2014","journal-title":"Intern Med"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib71","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/jamaophthalmol.2013.6281","article-title":"Retinal vasoproliferative tumors in 6 patients with neurofibromatosis type 1","volume":"132","author":"Shields","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"10.1016\/j.det.2019.05.015_bib72","first-page":"5609","article-title":"Neurofibromatosis type 1 and GIST: is there a correlation?","volume":"34","author":"Valencia","year":"2014","journal-title":"Anticancer Res"},{"issue":"12","key":"10.1016\/j.det.2019.05.015_bib73","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1002\/ajmg.a.35550","article-title":"Increased risk of breast cancer in women with NF1","volume":"158A","author":"Madanikia","year":"2012","journal-title":"Am J Med Genet A"},{"issue":"12","key":"10.1016\/j.det.2019.05.015_bib74","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1002\/ajmg.a.35560","article-title":"Breast cancer and other neoplasms in women with neurofibromatosis type 1: a retrospective review of cases in the Detroit metropolitan area","volume":"158A","author":"Wang","year":"2012","journal-title":"Am J Med Genet A"},{"issue":"9","key":"10.1016\/j.det.2019.05.015_bib75","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1038\/bjc.2015.78","article-title":"Age-specific risk of breast cancer in women with neurofibromatosis type 1","volume":"112","author":"Seminog","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.det.2019.05.015_bib76","series-title":"The genetic basis of human cancer","first-page":"423","article-title":"Neurofibromatosis type 1","author":"Gutmann","year":"1998"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib77","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0190-9622(80)80254-4","article-title":"Pathophysiology of neurofibromatosis. IV. Dermatologic insights into heterogeneity and pathogenesis","volume":"3","author":"Riccardi","year":"1980","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2019.05.015_bib78","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1215\/15228517-2008-011","article-title":"Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1","volume":"10","author":"Mautner","year":"2008","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib79","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1148\/radiol.2503080700","article-title":"Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images","volume":"250","author":"Cai","year":"2009","journal-title":"Radiology"},{"issue":"7","key":"10.1016\/j.det.2019.05.015_bib80","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00432-008-0523-y","article-title":"Differentiation between neurofibromas and malignant peripheral nerve sheath tumors in neurofibromatosis 1 evaluated by MRI","volume":"135","author":"Matsumine","year":"2009","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib81","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ejrad.2008.10.024","article-title":"Whole body MR imaging in neurofibromatosis type 1","volume":"69","author":"Van Meerbeeck","year":"2009","journal-title":"Eur J Radiol"},{"issue":"4","key":"10.1016\/j.det.2019.05.015_bib82","doi-asserted-by":"crossref","first-page":"e35711","DOI":"10.1371\/journal.pone.0035711","article-title":"Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis","volume":"7","author":"Plotkin","year":"2012","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.det.2019.05.015_bib83","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1474-4422(14)70063-8","article-title":"Neurofibromatosis type 1: a multidisciplinary approach to care","volume":"13","author":"Hirbe","year":"2014","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1016\/j.det.2019.05.015_bib84","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1212\/01.wnl.0000250332.89420.e6","article-title":"NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight","volume":"68","author":"Dombi","year":"2007","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib85","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/jmg.2008.061051","article-title":"Longitudinal study of neurofibromatosis 1 associated plexiform neurofibromas","volume":"46","author":"Tucker","year":"2009","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.det.2019.05.015_bib86","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1750-1172-7-75","article-title":"Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1","volume":"7","author":"Nguyen","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib87","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/1097-0142(19800101)45:1<126::AID-CNCR2820450122>3.0.CO;2-U","article-title":"Neurofibrosarcoma","volume":"45","author":"Storm","year":"1980","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.det.2019.05.015_bib88","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1086\/320121","article-title":"Mortality in neurofibromatosis 1: an analysis using U.S. death certificates","volume":"68","author":"Rasmussen","year":"2001","journal-title":"Am J Hum Genet"},{"issue":"5","key":"10.1016\/j.det.2019.05.015_bib89","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/jmg.39.5.311","article-title":"Malignant peripheral nerve sheath tumours in neurofibromatosis 1","volume":"39","author":"Evans","year":"2002","journal-title":"J\u00a0Med Genet"},{"issue":"4A","key":"10.1016\/j.det.2019.05.015_bib90","first-page":"1957","article-title":"Malignant peripheral nerve sheath tumors (MPNST) in NF1-affected children","volume":"27","author":"Friedrich","year":"2007","journal-title":"Anticancer Res"},{"issue":"7","key":"10.1016\/j.det.2019.05.015_bib91","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/jmg.2006.048140","article-title":"Further evidence of the increased risk for malignant peripheral nerve sheath tumour from a Scottish cohort of patients with neurofibromatosis type 1","volume":"44","author":"McCaughan","year":"2007","journal-title":"J\u00a0Med Genet"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib92","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/archderm.139.2.187","article-title":"Clinical risk factors for mortality in patients with neurofibromatosis 1: a cohort study of 378 patients","volume":"139","author":"Khosrotehrani","year":"2003","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.det.2019.05.015_bib93","first-page":"1573","article-title":"International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis","volume":"62","author":"Ferner","year":"2002","journal-title":"Cancer Res"},{"issue":"16","key":"10.1016\/j.det.2019.05.015_bib94","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1200\/JCO.2005.03.8349","article-title":"Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy","volume":"24","author":"Sharif","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.det.2019.05.015_bib95","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1086\/374821","article-title":"Elevated risk for MPNST in NF1 microdeletion patients","volume":"72","author":"De Raedt","year":"2003","journal-title":"Am J Hum Genet"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib96","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/ajmg.a.30394","article-title":"Subcutaneous neurofibromas are associated with mortality in neurofibromatosis 1: a cohort study of 703 patients","volume":"132A","author":"Khosrotehrani","year":"2005","journal-title":"Am J Med Genet A"},{"issue":"11","key":"10.1016\/j.det.2019.05.015_bib97","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1136\/jmg.2004.021683","article-title":"Neurofibromatous neuropathy in neurofibromatosis 1 (NF1)","volume":"41","author":"Ferner","year":"2004","journal-title":"J\u00a0Med Genet"},{"issue":"5","key":"10.1016\/j.det.2019.05.015_bib98","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/humu.9193","article-title":"Constitutional NF1 mutations in neurofibromatosis 1 patients with malignant peripheral nerve sheath tumors","volume":"22","author":"Kluwe","year":"2003","journal-title":"Hum Mutat"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib99","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1212\/01.wnl.0000168830.79997.13","article-title":"Association between benign and malignant peripheral nerve sheath tumors in NF1","volume":"65","author":"Tucker","year":"2005","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib100","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11060-013-1293-1","article-title":"Benign whole body tumor volume is a risk factor for malignant peripheral nerve sheath tumors in neurofibromatosis type 1","volume":"116","author":"Nguyen","year":"2014","journal-title":"J\u00a0Neurooncol"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib101","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s002470050082","article-title":"MR imaging differentiation of benign and malignant peripheral nerve sheath tumors: use of the target sign","volume":"27","author":"Bhargava","year":"1997","journal-title":"Pediatr Radiol"},{"issue":"6","key":"10.1016\/j.det.2019.05.015_bib102","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1007\/s00439-005-1265-4","article-title":"Extensively high load of internal tumors determined by whole body MRI scanning in a patient with neurofibromatosis type 1 and a non-LCR-mediated 2-Mb deletion in 17q11.2","volume":"116","author":"Kehrer-Sawatzki","year":"2005","journal-title":"Hum Genet"},{"issue":"6","key":"10.1016\/j.det.2019.05.015_bib103","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1007\/s00261-003-0040-z","article-title":"Mesenteric involvement in neurofibromatosis type 1: CT and MRI findings in two cases","volume":"28","author":"Kosucu","year":"2003","journal-title":"Abdom Imaging"},{"issue":"6","key":"10.1016\/j.det.2019.05.015_bib104","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.2214\/AJR.09.2724","article-title":"MRI features in the differentiation of malignant peripheral nerve sheath tumors and neurofibromas","volume":"194","author":"Wasa","year":"2010","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"10.1016\/j.det.2019.05.015_bib105","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S1064-9689(21)00650-4","article-title":"The role of MR imaging in soft tissue tumor evaluation: perspective of the orthopedic oncologist and musculoskeletal pathologist","volume":"8","author":"Frassica","year":"2000","journal-title":"Magn Reson Imaging Clin N Am"},{"issue":"8","key":"10.1016\/j.det.2019.05.015_bib106","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.3174\/ajnr.A3910","article-title":"Conventional and functional MR imaging of peripheral nerve sheath tumors: initial experience","volume":"35","author":"Demehri","year":"2014","journal-title":"AJNR Am J Neuroradiol"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib107","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jnnp.68.3.353","article-title":"Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1","volume":"68","author":"Ferner","year":"2000","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib108","doi-asserted-by":"crossref","first-page":"e85954","DOI":"10.1371\/journal.pone.0085954","article-title":"Utility of 18F-FDG PET with a semi-quantitative index in the detection of sarcomatous transformation in patients with neurofibromatosis type 1","volume":"9","author":"Combemale","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib109","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00330-013-3020-x","article-title":"18F-FDG PET\/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off","volume":"24","author":"Salamon","year":"2014","journal-title":"Eur Radiol"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib110","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2967\/jnumed.114.142372","article-title":"18F-FDG PET\/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization","volume":"56","author":"Chirindel","year":"2015","journal-title":"J\u00a0Nucl Med"},{"issue":"12","key":"10.1016\/j.det.2019.05.015_bib111","doi-asserted-by":"crossref","first-page":"e0143305","DOI":"10.1371\/journal.pone.0143305","article-title":"Nerve sheath tumors in neurofibromatosis type 1: assessment of whole-body metabolic tumor burden using F-18-FDG PET\/CT","volume":"10","author":"Salamon","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib112","doi-asserted-by":"crossref","first-page":"e0151809","DOI":"10.1371\/journal.pone.0151809","article-title":"Metabolic tumour burden measured by 18F-FDG PET\/CT predicts malignant transformation in patients with neurofibromatosis type-1","volume":"11","author":"Van Der Gucht","year":"2016","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.det.2019.05.015_bib113","doi-asserted-by":"crossref","first-page":"e0138386","DOI":"10.1371\/journal.pone.0138386","article-title":"Diagnostic accuracy of PET\/CT-guided percutaneous biopsies for malignant peripheral nerve sheath tumors in neurofibromatosis type 1 patients","volume":"10","author":"Brahmi","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.det.2019.05.015_bib114","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jpeds.2015.07.001","article-title":"The use of magnetic resonance imaging screening for optic pathway gliomas in children with neurofibromatosis type 1","volume":"167","author":"Prada","year":"2015","journal-title":"J\u00a0Pediatr"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib115","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ejpn.2015.12.002","article-title":"Systematic MRI in NF1 children under six years of age for the diagnosis of optic pathway gliomas. Study and outcome of a French cohort","volume":"20","author":"Blanchard","year":"2016","journal-title":"Eur J Paediatr Neurol"},{"issue":"8","key":"10.1016\/j.det.2019.05.015_bib116","first-page":"4095","article-title":"Optic pathway glioma and cerebral focal abnormal signal intensity in patients with neurofibromatosis type 1: characteristics, treatment choices and follow-up in 134\u00a0affected individuals and a brief review of the literature","volume":"36","author":"Friedrich","year":"2016","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.det.2019.05.015_bib117","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3928\/01913913-20160810-03","article-title":"Optic gliomas in neurofibromatosis type 1","volume":"53","author":"Parkhurst","year":"2016","journal-title":"J\u00a0Pediatr Ophthalmol Strabismus"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib118","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13023-017-0588-2","article-title":"Non-optic glioma in adults and children with neurofibromatosis 1","volume":"12","author":"Sellmer","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib119","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13023-018-0811-9","article-title":"Serial MRIs provide novel insight into natural history of optic pathway gliomas in patients with neurofibromatosis 1","volume":"13","author":"Sellmer","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"10.1016\/j.det.2019.05.015_bib120","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0161-6420(84)34217-8","article-title":"von Recklinghausen neurofibromatosis. II. Incidence of optic gliomata","volume":"91","author":"Lewis","year":"1984","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib121","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0022-3476(94)70122-9","article-title":"Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study","volume":"125","author":"Listernick","year":"1994","journal-title":"J\u00a0Pediatr"},{"issue":"5","key":"10.1016\/j.det.2019.05.015_bib122","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S0022-3476(89)80137-4","article-title":"Optic gliomas in children with neurofibromatosis type 1","volume":"114","author":"Listernick","year":"1989","journal-title":"J\u00a0Pediatr"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib123","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/ana.410410204","article-title":"Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force","volume":"41","author":"Listernick","year":"1997","journal-title":"Ann Neurol"},{"issue":"10","key":"10.1016\/j.det.2019.05.015_bib124","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1212\/01.WNL.0000144341.16830.01","article-title":"Late-onset optic pathway tumors in children with neurofibromatosis 1","volume":"63","author":"Listernick","year":"2004","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib125","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/ana.21107","article-title":"Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations","volume":"61","author":"Listernick","year":"2007","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib126","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/ana.21107","article-title":"Understanding vision loss from optic pathway glioma in neurofibromatosis type 1","volume":"61","author":"Freret","year":"2007","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.det.2019.05.015_bib127","doi-asserted-by":"crossref","first-page":"E3","DOI":"10.3171\/FOC-07\/11\/E3","article-title":"Syndromic and sporadic pediatric optic pathway gliomas: review of clinical and histopathological differences and treatment implications","volume":"23","author":"Shamji","year":"2007","journal-title":"Neurosurg Focus"},{"issue":"7","key":"10.1016\/j.det.2019.05.015_bib128","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1002\/pbc.22198","article-title":"Natural history and outcome of optic pathway gliomas in children","volume":"53","author":"Nicolin","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"Pt 1","key":"10.1016\/j.det.2019.05.015_bib129","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/brain\/awg016","article-title":"Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients","volume":"126","author":"Guillamo","year":"2003","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib130","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ajo.2003.09.055","article-title":"Optic radiation involvement in optic pathway gliomas in neurofibromatosis","volume":"137","author":"Liu","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.det.2019.05.015_bib131","series-title":"Youmans neurological surgery","first-page":"916","article-title":"Genetic syndromes associated with brain tumors","author":"Strowd","year":"2017"},{"issue":"7","key":"10.1016\/j.det.2019.05.015_bib132","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00381-014-2374-y","article-title":"Suprasellar pilocytic astrocytoma: one national centre's experience","volume":"30","author":"Mandiwanza","year":"2014","journal-title":"Childs Nerv Syst"},{"issue":"4","key":"10.1016\/j.det.2019.05.015_bib133","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1227\/01.NEU.0000298904.63635.2D","article-title":"Brainstem lesions in neurofibromatosis type 1","volume":"61","author":"Ullrich","year":"2007","journal-title":"Neurosurgery"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib134","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1212\/WNL.39.3.373","article-title":"The significance of MRI abnormalities in children with neurofibromatosis","volume":"39","author":"Duffner","year":"1989","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib135","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/ajmg.a.20656","article-title":"Longitudinal evolution of unidentified bright objects in children with neurofibromatosis-1","volume":"129A","author":"Kraut","year":"2004","journal-title":"Am J Med Genet A"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib136","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1148\/radiology.195.3.7754001","article-title":"Neurofibromatosis type 1: pathologic substrate of high-signal-intensity foci in the brain","volume":"195","author":"DiPaolo","year":"1995","journal-title":"Radiology"},{"issue":"7","key":"10.1016\/j.det.2019.05.015_bib137","first-page":"1333","article-title":"Three-dimensional multivoxel proton MR spectroscopy of the brain in children with neurofibromatosis type 1","volume":"20","author":"Gonen","year":"1999","journal-title":"AJNR Am J Neuroradiol"},{"issue":"18","key":"10.1016\/j.det.2019.05.015_bib138","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJM199105023241807","article-title":"Lisch nodules in Neurofibromatosis type 1","volume":"324","author":"Lubs","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib139","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/BF02307012","article-title":"Choroidal ganglioneuroma in neurofibromatosis","volume":"220","author":"Woog","year":"1983","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"10.1016\/j.det.2019.05.015_bib140","doi-asserted-by":"crossref","first-page":"586","DOI":"10.4103\/ijo.IJO_1095_17","article-title":"Multimodal imaging of choroidal nodules in neurofibromatosis type-1","volume":"66","author":"Kumar","year":"2018","journal-title":"Indian J Ophthalmol"},{"issue":"6","key":"10.1016\/j.det.2019.05.015_bib141","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ejim.2014.04.004","article-title":"Is it time to change the neurofibromatosis 1 diagnostic criteria?","volume":"25","author":"Tadini","year":"2014","journal-title":"Eur J Intern Med"},{"issue":"5","key":"10.1016\/j.det.2019.05.015_bib142","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3928\/01913913-20160719-05","article-title":"Choroidal freckling in pediatric patients affected by neurofibromatosis type 1","volume":"53","author":"Vagge","year":"2016","journal-title":"J\u00a0Pediatr Ophthalmol Strabismus"},{"issue":"10","key":"10.1016\/j.det.2019.05.015_bib143","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1002\/ajmg.a.33045","article-title":"Skeletal abnormalities in neurofibromatosis type 1: approaches to therapeutic options","volume":"149a","author":"Elefteriou","year":"2009","journal-title":"Am J Med Genet A"},{"issue":"5","key":"10.1016\/j.det.2019.05.015_bib144","first-page":"1751","article-title":"Dysplasia of the orbit and adjacent bone associated with plexiform neurofibroma and ocular disease in 42 NF-1 patients","volume":"30","author":"Friedrich","year":"2010","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1016\/j.det.2019.05.015_bib145","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/jmg.2008.061895","article-title":"Bone health and fracture rate in individuals with neurofibromatosis 1 (NF1)","volume":"46","author":"Tucker","year":"2009","journal-title":"J\u00a0Med Genet"},{"issue":"11","key":"10.1016\/j.det.2019.05.015_bib146","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.crad.2004.04.006","article-title":"Assessment of vertebral scalloping in neurofibromatosis type 1 with plain radiography and MRI","volume":"59","author":"Tsirikos","year":"2004","journal-title":"Clin Radiol"},{"issue":"7","key":"10.1016\/j.det.2019.05.015_bib147","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1288\/00005537-198607000-00005","article-title":"Head and neck manifestations of neurofibromatosis","volume":"96","author":"White","year":"1986","journal-title":"Laryngoscope"},{"key":"10.1016\/j.det.2019.05.015_bib148","series-title":"Neurofibromatosis: phenotype, natural history, and pathogenesis","first-page":"29","author":"Riccardi","year":"1986"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib149","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/1096-8628(20001113)95:2<108::AID-AJMG4>3.0.CO;2-0","article-title":"Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis 1","volume":"95","author":"Lin","year":"2000","journal-title":"Am J Med Genet"},{"issue":"4","key":"10.1016\/j.det.2019.05.015_bib150","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/cge.12072","article-title":"Cardiac characterization of 16 patients with large NF1 gene deletions","volume":"84","author":"Nguyen","year":"2013","journal-title":"Clin Genet"},{"key":"10.1016\/j.det.2019.05.015_bib151","first-page":"458543","article-title":"Neurofibromatosis type 1 complicated by atypical coarctation of the thoracic aorta","volume":"2013","author":"Kimura","year":"2013","journal-title":"Case Rep Pediatr"},{"issue":"4","key":"10.1016\/j.det.2019.05.015_bib152","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/ckj\/sfu054","article-title":"Neurofibromatosis type 1-associated hypertension secondary to coarctation of the thoracic aorta","volume":"7","author":"Mavani","year":"2014","journal-title":"Clin Kidney J"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib153","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1017\/S1047951113002230","article-title":"Cor triatriatum dexter and coarctation of the aorta--a rare association in a 7-year-old child with type 1 neurofibromatosis","volume":"25","author":"Omeje","year":"2015","journal-title":"Cardiol Young"},{"issue":"1098","key":"10.1016\/j.det.2019.05.015_bib154","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/postgradmedj-2016-134460","article-title":"A\u00a0case of coarctation of the abdominal aorta and renal artery stenosis due to neurofibromatosis type 1","volume":"93","author":"Veean","year":"2017","journal-title":"Postgrad Med J"},{"issue":"5","key":"10.1016\/j.det.2019.05.015_bib155","first-page":"1582","article-title":"von Recklinghausen's disease and pheochromocytomas","volume":"162","author":"Walther","year":"1999","journal-title":"J\u00a0Urol"},{"issue":"8\u20139","key":"10.1016\/j.det.2019.05.015_bib156","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s004679900260","article-title":"Renovascular disease and hypertension in children with neurofibromatosis","volume":"14","author":"Fossali","year":"2000","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.det.2019.05.015_bib157","series-title":"Neurofibromatosis type 1","first-page":"55","article-title":"The cognitive profile of NF1 children: therapeutic implications","author":"Pride","year":"2012"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib158","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1469-8749.2012.04399.x","article-title":"Behaviour in children with neurofibromatosis type 1: cognition, executive function, attention, emotion, and social competence","volume":"55","author":"Lehtonen","year":"2013","journal-title":"Dev Med Child Neurol"},{"issue":"1\u20132","key":"10.1016\/j.det.2019.05.015_bib159","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0022-510X(96)00022-6","article-title":"Intellectual impairment in neurofibromatosis 1","volume":"138","author":"Ferner","year":"1996","journal-title":"J\u00a0Neurol Sci"},{"issue":"4","key":"10.1016\/j.det.2019.05.015_bib160","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1212\/WNL.48.4.1121","article-title":"Cognitive function and academic performance in neurofibromatosis. 1: consensus statement from the NF1 Cognitive Disorders Task Force","volume":"48","author":"North","year":"1997","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib161","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<45::AID-AJMG9>3.0.CO;2-J","article-title":"Cognitive impairment in neurofibromatosis type 1","volume":"89","author":"Ozonoff","year":"1999","journal-title":"Am J Med Genet"},{"issue":"6","key":"10.1016\/j.det.2019.05.015_bib162","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/ajmg.a.35915","article-title":"Sleep disturbance as part of the neurofibromatosis type 1 phenotype in adults","volume":"161A","author":"Leschziner","year":"2013","journal-title":"Am J Med Genet A"},{"issue":"11","key":"10.1016\/j.det.2019.05.015_bib163","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1177\/0883073813500849","article-title":"Prevalence of sleep disturbances in children with neurofibromatosis type 1","volume":"28","author":"Licis","year":"2013","journal-title":"J\u00a0Child Neurol"},{"issue":"9","key":"10.1016\/j.det.2019.05.015_bib164","first-page":"561","article-title":"Prevalence of sleep disorders in patients with neurofibromatosis type 1","volume":"30","author":"Marana Perez","year":"2015","journal-title":"Neurologia"},{"issue":"6","key":"10.1016\/j.det.2019.05.015_bib165","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/ped.12375","article-title":"Migraine is frequent in children and adolescents with neurofibromatosis type 1","volume":"56","author":"Pinho","year":"2014","journal-title":"Pediatr Int"},{"issue":"10","key":"10.1016\/j.det.2019.05.015_bib166","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1002\/ajmg.a.37186","article-title":"Prevalence and clinical presentation of headache in a national neurofibromatosis 1 service and impact on quality of life","volume":"167a","author":"Afridi","year":"2015","journal-title":"Am J Med Genet A"},{"issue":"10","key":"10.1016\/j.det.2019.05.015_bib167","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1111\/epi.12348","article-title":"Epilepsy in individuals with neurofibromatosis type 1","volume":"54","author":"Ostendorf","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.det.2019.05.015_bib168","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jocn.2016.10.048","article-title":"Hippocampal sclerosis and associated focal cortical dysplasia-related epilepsy in neurofibromatosis type I","volume":"37","author":"Gales","year":"2017","journal-title":"J\u00a0Clin Neurosci"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib169","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2340\/0001555575136140","article-title":"Life expectancy, mortality and prognostic factors in neurofibromatosis type 1. A twelve-year follow-up of an epidemiological study in Goteborg, Sweden","volume":"75","author":"Zoller","year":"1995","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.det.2019.05.015_bib170","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1750-1172-6-11","article-title":"Mortality associated with neurofibromatosis type 1: a study based on Italian death certificates (1995-2006)","volume":"6","author":"Masocco","year":"2011","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib171","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11060-013-1195-2","article-title":"Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature","volume":"114","author":"Vranceanu","year":"2013","journal-title":"J\u00a0Neurooncol"},{"issue":"6","key":"10.1016\/j.det.2019.05.015_bib172","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/ajmg.a.36466","article-title":"Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis","volume":"164a","author":"Merker","year":"2014","journal-title":"Am J Med Genet A"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib173","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s11060-015-1725-1","article-title":"Quality of life among children and adolescents with neurofibromatosis 1: a systematic review of the literature","volume":"122","author":"Vranceanu","year":"2015","journal-title":"J\u00a0Neurooncol"},{"issue":"5","key":"10.1016\/j.det.2019.05.015_bib174","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/cge.12551","article-title":"Depression among adults with neurofibromatosis type 1: prevalence and impact on quality of life","volume":"88","author":"Cohen","year":"2015","journal-title":"Clin Genet"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib175","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1542\/peds.2007-3364","article-title":"Health supervision for children with neurofibromatosis","volume":"121","author":"Hersh","year":"2008","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib176","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/archdischild-2014-308084","article-title":"Annual review of children with neurofibromatosis type 1","volume":"101","author":"Dunning-Davies","year":"2016","journal-title":"Arch Dis Child Educ Pract Ed"},{"issue":"7","key":"10.1016\/j.det.2019.05.015_bib177","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/gim.2018.28","article-title":"Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"20","author":"Stewart","year":"2018","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib178","doi-asserted-by":"crossref","first-page":"9","DOI":"10.6004\/jnccn.2017.0003","article-title":"NCCN guidelines insights: genetic\/familial high-risk assessment: breast and ovarian, version 2.2017","volume":"15","author":"Daly","year":"2017","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib179","first-page":"172","article-title":"National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13-15, 1987","volume":"1","year":"1988","journal-title":"Neurofibromatosis"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib180","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jama.1997.03550010065042","article-title":"The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2","volume":"278","author":"Gutmann","year":"1997","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib181","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1542\/peds.2007-3204","article-title":"Neurofibromatosis type 1 revisited","volume":"123","author":"Williams","year":"2009","journal-title":"Pediatrics"},{"issue":"6 Pt 1","key":"10.1016\/j.det.2019.05.015_bib182","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S0190-9622(99)70075-7","article-title":"The diagnostic value of cafe-au-lait macules","volume":"40","author":"Landau","year":"1999","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib183","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1542\/pir.22.3.82","article-title":"Cafe au lait spots: the pediatrician's perspective","volume":"22","author":"Tekin","year":"2001","journal-title":"Pediatr Rev"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib184","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000368078","article-title":"Treatment of neurofibromas with a carbon dioxide laser: a retrospective cross-sectional study of 106 patients","volume":"230","author":"Meni","year":"2015","journal-title":"Dermatology"},{"issue":"6","key":"10.1016\/j.det.2019.05.015_bib185","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/00000637-199106000-00016","article-title":"Use of the carbon dioxide laser in treating multiple cutaneous neurofibromas","volume":"26","author":"Becker","year":"1991","journal-title":"Ann Plast Surg"},{"issue":"8","key":"10.1016\/j.det.2019.05.015_bib186","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.bjps.2007.03.035","article-title":"Electrosurgical excision technique for the treatment of multiple cutaneous lesions in neurofibromatosis type I","volume":"61","author":"Levine","year":"2008","journal-title":"J\u00a0Plast Reconstr Aesthet Surg"},{"issue":"4","key":"10.1016\/j.det.2019.05.015_bib187","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/jmg.2005.036319","article-title":"Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes","volume":"43","author":"Evans","year":"2006","journal-title":"J\u00a0Med Genet"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib188","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1477-7819-3-6","article-title":"Resection of small plexiform neurofibromas in neurofibromatosis type 1 children","volume":"3","author":"Friedrich","year":"2005","journal-title":"World J Surg Oncol"},{"issue":"12","key":"10.1016\/j.det.2019.05.015_bib189","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S1470-2045(12)70414-X","article-title":"Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial","volume":"13","author":"Robertson","year":"2012","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib190","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11060-009-0049-4","article-title":"Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model","volume":"98","author":"Demestre","year":"2010","journal-title":"J\u00a0Neurooncol"},{"issue":"26","key":"10.1016\/j.det.2019.05.015_bib191","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib192","first-page":"142","article-title":"Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1","volume":"118","author":"Dunn","year":"2013","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.det.2019.05.015_bib193","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejca.2015.12.015","article-title":"Management and prognosis of malignant peripheral nerve sheath tumors: the experience of the French Sarcoma Group (GSF-GETO)","volume":"56","author":"Valentin","year":"2016","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.det.2019.05.015_bib194","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/pbc.24245","article-title":"Metronomic therapy for malignant peripheral nerve sheath tumor in neurofibromatosis type 1","volume":"59","author":"Chaudhary","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.det.2019.05.015_bib195","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/1750-1172-8-127","article-title":"Chemotherapy for the treatment of malignant peripheral nerve sheath tumors in neurofibromatosis 1: a 10-year institutional review","volume":"8","author":"Zehou","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1016\/j.det.2019.05.015_bib196","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/neuonc\/2.4.213","article-title":"Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study","volume":"2","author":"Mahoney","year":"2000","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.det.2019.05.015_bib197","first-page":"747","article-title":"Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas","volume":"86","author":"Packer","year":"1997","journal-title":"J\u00a0Neurosurg"},{"issue":"5","key":"10.1016\/j.det.2019.05.015_bib198","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.1993.11.5.850","article-title":"Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood","volume":"11","author":"Packer","year":"1993","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.det.2019.05.015_bib199","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1215\/15228517-2007-031","article-title":"Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program","volume":"9","author":"Dalla Via","year":"2007","journal-title":"Neuro Oncol"},{"issue":"23","key":"10.1016\/j.det.2019.05.015_bib200","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1002\/cncr.29649","article-title":"Long-term visual outcome after chemotherapy for optic pathway glioma in children: site and age are strongly predictive","volume":"121","author":"Dodgshun","year":"2015","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.det.2019.05.015_bib201","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/neuonc\/nos076","article-title":"Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis","volume":"14","author":"Fisher","year":"2012","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib202","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/pbc.22967","article-title":"Visual outcome following chemotherapy for progressive optic pathway gliomas","volume":"57","author":"Shofty","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"10.1016\/j.det.2019.05.015_bib203","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/j.ejca.2010.03.028","article-title":"Does chemotherapy affect the visual outcome in children with optic pathway glioma? A systematic review of the evidence","volume":"46","author":"Moreno","year":"2010","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.det.2019.05.015_bib204","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","article-title":"Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference","volume":"49","author":"Northrup","year":"2013","journal-title":"Pediatr Neurol"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib205","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1590\/S0365-05962012000200001","article-title":"Tuberous sclerosis complex","volume":"87","author":"Rodrigues","year":"2012","journal-title":"An Bras Dermatol"},{"issue":"6","key":"10.1016\/j.det.2019.05.015_bib206","doi-asserted-by":"crossref","first-page":"e001493","DOI":"10.1161\/JAHA.114.001493","article-title":"Cardiovascular manifestations of tuberous sclerosis complex and summary of the revised diagnostic criteria and surveillance and management recommendations from the International Tuberous Sclerosis Consensus Group","volume":"3","author":"Hinton","year":"2014","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.det.2019.05.015_bib207","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1749-6632.1991.tb37754.x","article-title":"Epidemiology of tuberous sclerosis","volume":"615","author":"Osborne","year":"1991","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"10.1016\/j.det.2019.05.015_bib208","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1212\/WNL.35.4.600","article-title":"Incidence and prevalence of tuberous sclerosis in Rochester, Minnesota, 1950 through 1982","volume":"35","author":"Wiederholt","year":"1985","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib209","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/adc.78.2.159","article-title":"Tuberous sclerosis complex and Wolff-Parkinson-White syndrome","volume":"78","author":"O'Callaghan","year":"1998","journal-title":"Arch Dis Child"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib210","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/jmg.26.1.28","article-title":"Genetic aspects of tuberous sclerosis in the west of Scotland","volume":"26","author":"Sampson","year":"1989","journal-title":"J\u00a0Med Genet"},{"issue":"9639","key":"10.1016\/j.det.2019.05.015_bib211","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","article-title":"Tuberous sclerosis","volume":"372","author":"Curatolo","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.det.2019.05.015_bib212","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/jdv.13356","article-title":"Systemic effects of treatment with mTOR inhibitors in tuberous sclerosis complex: a comprehensive review","volume":"30","author":"Sadowski","year":"2016","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib213","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.pcl.2015.03.005","article-title":"Tuberous sclerosis complex","volume":"62","author":"DiMario","year":"2015","journal-title":"Pediatr Clin North Am"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib214","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1590\/abd1806-4841.20186972","article-title":"Tuberous sclerosis complex: review based on new diagnostic criteria","volume":"93","author":"Portocarrero","year":"2018","journal-title":"An Bras Dermatol"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib215","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/ng0992-37","article-title":"Linkage of an important gene locus for tuberous sclerosis to a chromosome 16 marker for polycystic kidney disease","volume":"2","author":"Kandt","year":"1992","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib216","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1469-1809.1994.tb01881.x","article-title":"Two loci for tuberous sclerosis: one on 9q34 and one on 16p13","volume":"58","author":"Povey","year":"1994","journal-title":"Ann Hum Genet"},{"issue":"6","key":"10.1016\/j.det.2019.05.015_bib217","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/hmg\/7.6.1053","article-title":"Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products","volume":"7","author":"van Slegtenhorst","year":"1998","journal-title":"Hum Mol Genet"},{"issue":"6","key":"10.1016\/j.det.2019.05.015_bib218","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S1097-2765(03)00220-X","article-title":"Insulin activation of Rheb, a mediator of mTOR\/S6K\/4E-BP signaling, is inhibited by TSC1 and 2","volume":"11","author":"Garami","year":"2003","journal-title":"Mol Cell"},{"issue":"15","key":"10.1016\/j.det.2019.05.015_bib219","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1101\/gad.1110003","article-title":"Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling","volume":"17","author":"Inoki","year":"2003","journal-title":"Genes Dev"},{"issue":"6","key":"10.1016\/j.det.2019.05.015_bib220","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/ncb995","article-title":"Rheb is an essential regulator of S6K in controlling cell growth in Drosophila","volume":"5","author":"Stocker","year":"2003","journal-title":"Nat Cell Biol"},{"issue":"21","key":"10.1016\/j.det.2019.05.015_bib221","doi-asserted-by":"crossref","first-page":"13571","DOI":"10.1073\/pnas.202476899","article-title":"Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling","volume":"99","author":"Tee","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"10.1016\/j.det.2019.05.015_bib222","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0960-9822(03)00506-2","article-title":"Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb","volume":"13","author":"Tee","year":"2003","journal-title":"Curr Biol"},{"issue":"6","key":"10.1016\/j.det.2019.05.015_bib223","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/ncb999","article-title":"Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins","volume":"5","author":"Zhang","year":"2003","journal-title":"Nat Cell Biol"},{"issue":"5","key":"10.1016\/j.det.2019.05.015_bib224","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/35010550","article-title":"The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho","volume":"2","author":"Lamb","year":"2000","journal-title":"Nat Cell Biol"},{"issue":"12","key":"10.1016\/j.det.2019.05.015_bib225","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1128\/MCB.00289-08","article-title":"The TSC1-TSC2 complex is required for proper activation of mTOR complex 2","volume":"28","author":"Huang","year":"2008","journal-title":"Mol Cell Biol"},{"issue":"6","key":"10.1016\/j.det.2019.05.015_bib226","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/jmg.2007.054304","article-title":"BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dube syndrome: a new series of 50 families and a review of published reports","volume":"45","author":"Toro","year":"2008","journal-title":"J\u00a0Med Genet"},{"issue":"7","key":"10.1016\/j.det.2019.05.015_bib227","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1177\/0883073813488664","article-title":"A\u00a0novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex","volume":"28","author":"Wheless","year":"2013","journal-title":"J\u00a0Child Neurol"},{"issue":"12","key":"10.1016\/j.det.2019.05.015_bib228","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1046\/j.1365-4362.1998.00495.x","article-title":"Skin lesions in children with tuberous sclerosis complex: their prevalence, natural course, and diagnostic significance","volume":"37","author":"Jozwiak","year":"1998","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2019.05.015_bib229","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0022-3476(70)80199-8","article-title":"White spots in tuberous sclerosis","volume":"77","author":"Hurwitz","year":"1970","journal-title":"J\u00a0Pediatr"},{"issue":"33","key":"10.1016\/j.det.2019.05.015_bib230","first-page":"2405","article-title":"Letter: significance of achromic spots in the infant","volume":"4","author":"Debard","year":"1975","journal-title":"Nouv Presse Med"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib231","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0022-3476(96)70066-5","article-title":"Prevalence of hypopigmented macules in a healthy population","volume":"129","author":"Vanderhooft","year":"1996","journal-title":"J\u00a0Pediatr"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib232","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2133.1996.d01-923.x","article-title":"The cutaneous features of tuberous sclerosis: a population study","volume":"135","author":"Webb","year":"1996","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib233","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/GIM.0b013e31803068c7","article-title":"Genotype\/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in\u00a0the United States","volume":"9","author":"Au","year":"2007","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib234","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1086\/316951","article-title":"Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs","volume":"68","author":"Dabora","year":"2001","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib235","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jaad.2009.08.042","article-title":"Acral lesions in tuberous sclerosis complex: insights into pathogenesis","volume":"63","author":"Aldrich","year":"2010","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.det.2019.05.015_bib236","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/archdermatol.2010.125","article-title":"Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis","volume":"146","author":"Haemel","year":"2010","journal-title":"Arch Dermatol"},{"issue":"10","key":"10.1016\/j.det.2019.05.015_bib237","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1177\/088307380001501003","article-title":"Usefulness of diagnostic criteria of tuberous sclerosis complex in pediatric patients","volume":"15","author":"Jozwiak","year":"2000","journal-title":"J\u00a0Child Neurol"},{"issue":"4","key":"10.1016\/j.det.2019.05.015_bib238","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jaad.2017.12.027","article-title":"Fibrous cephalic plaques in tuberous sclerosis complex","volume":"78","author":"Oyerinde","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2019.05.015_bib239","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.jaad.2006.11.019","article-title":"Oral findings in 58 adults with tuberous sclerosis complex","volume":"56","author":"Sparling","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.det.2019.05.015_bib240","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1136\/jmg.34.8.637","article-title":"Developmental enamel defects in tuberous sclerosis: a clinical genetic marker?","volume":"34","author":"Flanagan","year":"1997","journal-title":"J\u00a0Med Genet"},{"issue":"6","key":"10.1016\/j.det.2019.05.015_bib241","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0030-4220(89)90162-X","article-title":"Oral fibromatosis in tuberous sclerosis","volume":"68","author":"Lygidakis","year":"1989","journal-title":"Oral Surg Oral Med Oral Pathol"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib242","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0030-4220(91)90523-F","article-title":"Enamel pitting: a common symptom of tuberous sclerosis","volume":"71","author":"Mlynarczyk","year":"1991","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"10.1016\/j.det.2019.05.015_bib243","series-title":"Tuberous sclerosis complex: genes, clinical features, and therapeutics","first-page":"285","article-title":"Pathogenesis of TSC\u00a0in the brain","author":"Crino","year":"2010"},{"issue":"6","key":"10.1016\/j.det.2019.05.015_bib244","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.pediatrneurol.2013.08.017","article-title":"Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012","volume":"49","author":"Roth","year":"2013","journal-title":"Pediatr Neurol"},{"issue":"7","key":"10.1016\/j.det.2019.05.015_bib245","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1474-4422(15)00069-1","article-title":"Neurological and neuropsychiatric aspects of tuberous sclerosis complex","volume":"14","author":"Curatolo","year":"2015","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib246","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1136\/archdischild-2013-304948","article-title":"Annual review of children with tuberous sclerosis","volume":"100","author":"Ng","year":"2015","journal-title":"Arch Dis Child Educ Pract Ed"},{"issue":"6","key":"10.1016\/j.det.2019.05.015_bib247","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0002-8703(97)70032-2","article-title":"Pediatric primary benign cardiac tumors: a 15-year review","volume":"134","author":"Beghetti","year":"1997","journal-title":"Am Heart J"},{"issue":"4","key":"10.1016\/j.det.2019.05.015_bib248","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/ajmg.1320370402","article-title":"Incidence of tuberous sclerosis in patients with cardiac rhabdomyoma","volume":"37","author":"Harding","year":"1990","journal-title":"Am J Med Genet"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib249","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/0735-1097(95)80031-B","article-title":"Diagnosis and management of fetal cardiac tumors: a multicenter experience and review of published reports","volume":"26","author":"Holley","year":"1995","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.det.2019.05.015_bib250","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1471-2261-14-66","article-title":"Rhabdomyomas and tuberous sclerosis complex: our experience in 33 cases","volume":"14","author":"Sciacca","year":"2014","journal-title":"BMC Cardiovasc Disord"},{"issue":"6","key":"10.1016\/j.det.2019.05.015_bib251","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/088307389901400610","article-title":"Tuberous sclerosis consensus conference: recommendations for diagnostic evaluation. National tuberous sclerosis association","volume":"14","author":"Roach","year":"1999","journal-title":"J\u00a0Child Neurol"},{"key":"10.1016\/j.det.2019.05.015_bib252","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s13023-014-0182-9","article-title":"TOSCA - first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex","volume":"9","author":"Kingswood","year":"2014","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib253","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.eururo.2016.01.048","article-title":"Natural history of renal angiomyolipoma (AML): most patients with large AMLs\u00a0>4cm can be offered active surveillance as an initial management strategy","volume":"70","author":"Bhatt","year":"2016","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.det.2019.05.015_bib254","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2214\/ajr.182.4.1821027","article-title":"Frequency and imaging appearance of hepatic angiomyolipomas in pediatric and adult patients with tuberous sclerosis","volume":"182","author":"Fricke","year":"2004","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.det.2019.05.015_bib255","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/PCR.0b013e31819c2114","article-title":"Angiomyolipoma of the liver","volume":"14","author":"Nakhleh","year":"2009","journal-title":"Pathol Case Rev"},{"issue":"7","key":"10.1016\/j.det.2019.05.015_bib256","doi-asserted-by":"crossref","first-page":"32","DOI":"10.15844\/pedneurbriefs-30-7-1","article-title":"Tuberous sclerosis complex: a roadmap for future research","volume":"30","author":"Jeong","year":"2016","journal-title":"Pediatr Neurol Briefs"},{"issue":"7\u20138","key":"10.1016\/j.det.2019.05.015_bib257","doi-asserted-by":"crossref","first-page":"E507","DOI":"10.5489\/cuaj.2532","article-title":"Composite renal cell carcinoma and angiomyolipoma in a patient with Tuberous sclerosis: a diagnostic dilemma","volume":"9","author":"Kakkar","year":"2015","journal-title":"Can Urol Assoc J"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib258","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/path.4827","article-title":"New developments in the genetics and pathogenesis of tumours in tuberous sclerosis complex","volume":"241","author":"Lam","year":"2017","journal-title":"J\u00a0Pathol"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib259","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1183\/09031936.00076209","article-title":"European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis","volume":"35","author":"Johnson","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.det.2019.05.015_bib260","series-title":"Tuberous sclerosis complex: genes, clinical features, and therapeutics","first-page":"345","article-title":"Lymphangioleiomyomatosis and pulmonary disease in TSC","author":"McCormack","year":"2010"},{"issue":"4","key":"10.1016\/j.det.2019.05.015_bib261","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1164\/ajrccm.164.4.2101154","article-title":"Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex","volume":"164","author":"Moss","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.det.2019.05.015_bib262","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.crad.2011.02.009","article-title":"Radiological evidence of lymphangioleiomyomatosis in female and male patients with tuberous sclerosis complex","volume":"66","author":"Adriaensen","year":"2011","journal-title":"Clin Radiol"},{"issue":"5","key":"10.1016\/j.det.2019.05.015_bib263","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/RCT.0b013e318264e404","article-title":"Multifocal micronodular pneumocyte hyperplasia: computed tomographic appearance and follow-up in tuberous sclerosis complex","volume":"36","author":"Muzykewicz","year":"2012","journal-title":"J\u00a0Comput Assist Tomogr"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib264","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1378\/chest.12-2813","article-title":"Lymphangioleiomyomatosis screening in women with tuberous sclerosis","volume":"144","author":"Cudzilo","year":"2013","journal-title":"Chest"},{"issue":"5783","key":"10.1016\/j.det.2019.05.015_bib265","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/bmj.4.5783.323","article-title":"Prognostic implications of electroencephalographic findings of hypsarrhythmia in first year of life","volume":"4","author":"Friedman","year":"1971","journal-title":"Br Med J"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib266","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1469-8749.1987.tb02135.x","article-title":"Psychiatric disorder among children with tuberous sclerosis","volume":"29","author":"Hunt","year":"1987","journal-title":"Dev Med Child Neurol"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib267","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/BF01048239","article-title":"Autism and tuberous sclerosis","volume":"22","author":"Smalley","year":"1992","journal-title":"J\u00a0Autism Dev Disord"},{"issue":"11","key":"10.1016\/j.det.2019.05.015_bib268","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/adc.2011.211995","article-title":"The Tuberous sclerosis 2000 study: presentation, initial assessments and implications for diagnosis and management","volume":"96","author":"Yates","year":"2011","journal-title":"Arch Dis Child"},{"issue":"4","key":"10.1016\/j.det.2019.05.015_bib269","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.002","article-title":"Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference","volume":"49","author":"Krueger","year":"2013","journal-title":"Pediatr Neurol"},{"issue":"5","key":"10.1016\/j.det.2019.05.015_bib270","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/lsm.20939","article-title":"New technique using combined pulsed dye laser and fractional resurfacing for treating facial angiofibromas in tuberous sclerosis","volume":"42","author":"Weiss","year":"2010","journal-title":"Lasers Surg Med"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib271","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/11634580-000000000-00000","article-title":"Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin","volume":"12","author":"Koenig","year":"2012","journal-title":"Drugs R D"},{"issue":"4","key":"10.1016\/j.det.2019.05.015_bib272","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1365-2133.2011.10476.x","article-title":"Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(-1) ) in two patients with tuberous sclerosis","volume":"165","author":"Mutizwa","year":"2011","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib273","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jaad.2017.04.005","article-title":"Long-term treatment of cutaneous manifestations of tuberous sclerosis complex with topical 1% sirolimus cream: a prospective study of 25 patients","volume":"77","author":"Malissen","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib274","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/jamadermatol.2016.3545","article-title":"Efficacy and safety of topical sirolimus therapy for facial angiofibromas in the tuberous sclerosis complex: a randomized clinical trial","volume":"153","author":"Wataya-Kaneda","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.det.2019.05.015_bib275","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/1756287216641353","article-title":"Optimal treatment of tuberous sclerosis complex associated renal angiomyolipomata: a systematic review","volume":"8","author":"Bissler","year":"2016","journal-title":"Ther Adv Urol"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib276","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00706730","article-title":"Intraventricular tumors in tuberous sclerosis","volume":"1","author":"Frerebeau","year":"1985","journal-title":"Childs Nerv Syst"},{"issue":"4","key":"10.1016\/j.det.2019.05.015_bib277","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s00381-002-0700-2","article-title":"Subependymal giant cell astrocytoma in children with tuberous sclerosis","volume":"19","author":"Cuccia","year":"2003","journal-title":"Childs Nerv Syst"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib278","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00381-010-1159-1","article-title":"The diagnosis and treatment of subependymal giant cell astrocytoma combined with tuberous sclerosis","volume":"27","author":"Jiang","year":"2011","journal-title":"Childs Nerv Syst"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib279","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12519-010-0025-2","article-title":"Management of subependymal giant cell tumors in tuberous sclerosis complex: the neurosurgeon's perspective","volume":"6","author":"Berhouma","year":"2010","journal-title":"World J Pediatr"},{"issue":"8","key":"10.1016\/j.det.2019.05.015_bib280","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00381-011-1406-0","article-title":"The management of subependymal giant cell tumors in tuberous sclerosis: a clinician's perspective","volume":"27","author":"Moavero","year":"2011","journal-title":"Childs Nerv Syst"},{"issue":"8","key":"10.1016\/j.det.2019.05.015_bib281","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1212\/01.WNL.0000142039.14522.1A","article-title":"Subependymal giant cell tumors in tuberous sclerosis complex","volume":"63","author":"Goh","year":"2004","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib282","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1227\/01.NEU.0000249216.19591.5D","article-title":"Subependymal giant-cell astrocytomas in pediatric tuberous sclerosis disease: when should we operate?","volume":"60","author":"de Ribaupierre","year":"2007","journal-title":"Neurosurgery"},{"issue":"1","key":"10.1016\/j.det.2019.05.015_bib283","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13023-016-0553-5","article-title":"TuberOus SClerosis registry to increase disease awareness (TOSCA) - baseline data on 2093 patients","volume":"12","author":"Kingswood","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"10.1016\/j.det.2019.05.015_bib284","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2176\/nmc.38.287","article-title":"Glioblastoma following radiotherapy in a patient with tuberous sclerosis","volume":"38","author":"Matsumura","year":"1998","journal-title":"Neurol Med Chir (Tokyo)"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib285","first-page":"808","article-title":"Gamma Knife surgery for subependymal giant cell astrocytomas. Clinical article","volume":"114","author":"Park","year":"2011","journal-title":"J\u00a0Neurosurg"},{"issue":"3","key":"10.1016\/j.det.2019.05.015_bib286","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ana.20784","article-title":"Rapamycin causes regression of astrocytomas in tuberous sclerosis complex","volume":"59","author":"Franz","year":"2006","journal-title":"Ann Neurol"},{"issue":"19","key":"10.1016\/j.det.2019.05.015_bib287","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.det.2019.05.015_bib288","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s11940-011-0123-z","article-title":"Subependymal giant cell astrocytoma (SEGA) treatment update","volume":"13","author":"Campen","year":"2011","journal-title":"Curr Treat Options Neurol"},{"issue":"9861","key":"10.1016\/j.det.2019.05.015_bib289","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.det.2019.05.015_bib290","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejpn.2013.03.002","article-title":"Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex","volume":"17","author":"Kotulska","year":"2013","journal-title":"Eur J Paediatr Neurol"},{"issue":"6","key":"10.1016\/j.det.2019.05.015_bib291","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/ana.24523","article-title":"Everolimus for subependymal giant cell astrocytoma: 5-year final analysis","volume":"78","author":"Franz","year":"2015","journal-title":"Ann Neurol"},{"issue":"10056","key":"10.1016\/j.det.2019.05.015_bib292","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"French","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib293","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejpn.2009.03.003","article-title":"Early control of seizures improves long-term outcome in children with tuberous sclerosis complex","volume":"14","author":"Bombardieri","year":"2010","journal-title":"Eur J Paediatr Neurol"},{"issue":"6","key":"10.1016\/j.det.2019.05.015_bib294","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.ejpn.2012.05.004","article-title":"Management of epilepsy associated with tuberous sclerosis complex (TSC): clinical recommendations","volume":"16","author":"Curatolo","year":"2012","journal-title":"Eur J Paediatr Neurol"},{"issue":"5","key":"10.1016\/j.det.2019.05.015_bib295","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ejpn.2011.03.010","article-title":"Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex","volume":"15","author":"Jozwiak","year":"2011","journal-title":"Eur J Paediatr Neurol"},{"issue":"6","key":"10.1016\/j.det.2019.05.015_bib296","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ejpn.2007.03.010","article-title":"Current role of vigabatrin in infantile spasms","volume":"11","author":"Parisi","year":"2007","journal-title":"Eur J Paediatr Neurol"},{"issue":"7","key":"10.1016\/j.det.2019.05.015_bib297","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/j.1528-1167.2008.01589.x","article-title":"Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile","volume":"49","author":"Camposano","year":"2008","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.det.2019.05.015_bib298","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/epi.13499","article-title":"Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex","volume":"57","author":"Hess","year":"2016","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.det.2019.05.015_bib299","first-page":"281","article-title":"Renal angiomyolipoma: optimal treatment based on size and symptoms","volume":"49","author":"Dickinson","year":"1998","journal-title":"Clin Nephrol"},{"issue":"9869","key":"10.1016\/j.det.2019.05.015_bib300","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.det.2019.05.015_bib301","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jaad.2015.07.018","article-title":"Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus","volume":"73","author":"Nathan","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2019.05.015_bib302","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.det.2019.05.015_bib303","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and safety of sirolimus in lymphangioleiomyomatosis","volume":"364","author":"McCormack","year":"2011","journal-title":"N\u00a0Engl J Med"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863519300579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863519300579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:43:29Z","timestamp":1760006609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863519300579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":303,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0733863519300579"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2019.05.015","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phakomatoses","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2019.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}